Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21536653 | 0.88 | — | — | |
| SCHEMBL26351712 | 0.86 | NUDT1 (0.34) | — | |
| SCHEMBL15896625 | 0.85 | SRC (0.34) | RAB9ANPC1POLBCTDSP1 | |
| SCHEMBL21533859 | 0.82 | — | — | |
| SCHEMBL1911594 | 0.82 | SLC6A3 (0.40) | RAB9ANPC1ALDH1A1POLBLMNA | |
| SCHEMBL13220759 | 0.80 | LMNA (0.47) | RAB9ANPC1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL10246306 | 0.80 | LMNA (0.31) | RAB9APOLBLMNAATML3MBTL1 | |
| SCHEMBL1912687 | 0.80 | L3MBTL1 (0.49) | RAB9AALDH1A1POLBLMNAATM | |
| SCHEMBL13010776 | 0.78 | LMNA (0.30) | RAB9APOLBLMNAATML3MBTL1 | |
| SCHEMBL11922170 | 0.78 | SLC6A3 (0.45) | RAB9APOLBLMNAATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-20210061767-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-03-04 | — | — | US | disclosed |
| US-10829457-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-11-10 | — | — | US | disclosed |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | TNF, NFATC1, IL2 | RAB9A 728/4885NPC1 725/4885ALDH1A1 702/4885 |
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | RAB9A 3151/4885NPC1 2484/4885ALDH1A1 972/4885 |
| US-20210061767-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, DPYD, TYMP | RAB9A 4012/4885NPC1 2639/4885ALDH1A1 1672/4885 |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | RAB9A 3628/4885NPC1 1803/4885ALDH1A1 1207/4885 |
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | RAB9A 3969/4885NPC1 2179/4885ALDH1A1 2924/4885 |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | DPYD, DNPEP, DUT | RAB9A 3969/4885NPC1 2179/4885ALDH1A1 2924/4885 |
| US-10829457-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | RAB9A 4012/4885NPC1 2639/4885ALDH1A1 1672/4885 |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | UNG, DPYD, DUT | RAB9A 3416/4885NPC1 1841/4885ALDH1A1 970/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | RAB9A 4012/4885NPC1 2639/4885ALDH1A1 1672/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | RAB9A 3416/4885NPC1 1841/4885ALDH1A1 970/4885 |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, DPYD, TYMP | RAB9A 4012/4885NPC1 2639/4885ALDH1A1 1672/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | RAB9A 3151/4885NPC1 2484/4885ALDH1A1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.